Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
about
First trimester serum tests for Down's syndrome screeningThe utility of circulating LHCGR as a predictor of Down's syndrome in early pregnancy.Assessment of Foetal DNA in Maternal Blood - A Useful Tool in the Hands of Prenatal Specialists.First-trimester screening for neural tube defects using alpha-fetoprotein.Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies.Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis.Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening.First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.Aberrant "Barbed-Wire" Nuclear Projections of Neutrophils in Trisomy 18 (Edwards Syndrome).First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward SyndromeQuantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down's syndrome, preterm delivery and preeclampsia.Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysisThe associations of nuchal translucency and fetal abnormalities; significance and implications.Imaging clues in the prenatal diagnosis of syndromes and aneuploidy.Screening for Down syndrome.The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study.Discordance between ultrasound and cell free DNA screening for monosomy X.The IONA® Test: Development of an Automated Cell-Free DNA-Based Screening Test for Fetal Trisomies 13, 18, and 21 That Employs the Ion Proton Semiconductor Sequencing Platform.Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.Validation of a method for noninvasive prenatal testing for fetal aneuploidies risk and considerations for its introduction in the Public Health System.Nuchal translucency distributions for different chromosomal anomalies in a large unselected population cohort.QUAD versus cfDNA in an urban population in the second trimester for detection of trisomy 21: a cost sensitivity analysis.Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.Combined screening for preeclampsia and small for gestational age at 11-13 weeks.First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.First trimester maternal uterine artery Doppler examination in HIV-positive women.Impact of chorionicity on first-trimester nuchal translucency screening in ART twin pregnancies.A unified approach to risk assessment for fetal aneuploidies.A competing risks model in early screening for preeclampsia.A preliminary retrospective study about the relationship between ductus venosus Doppler indices, nuchal translucency (NT) and biochemical markers in the first and second trimester screening tests.Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13.The first trimester combined test for aneuploidies - a single center experience.First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow.First-trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13.Screening for trisomy 18 using traditional combined screening vs. ultrasound-based protocol in tertiary center environment.Maternal serum PAPP-A and free β-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.Cell-free DNA testing in the maternal blood in high-risk pregnancies after first-trimester combined screening.Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers.Does diurnal variation affect the first trimester fetal aneuploidy screening test biochemical parameters of fetuses with normal nuchal translucency?Screening and outcome of chromosomal abnormalities other than trisomy 21 in Northern Finland.
P2860
Q24187589-7FCDDAD3-2B2E-4543-B371-11DD875D183AQ33770074-B803E3F8-6527-4463-9059-C1D360C7F0C1Q34209281-DEB2C172-5473-4462-9189-D94586C48A63Q34257712-622B5194-7267-4941-9B12-B0B6F897FE52Q34496747-BFA0BD28-6B4C-4223-BCD1-88E99CD9DFAEQ35552815-0D0E6D9D-2354-469B-A866-67DD2621349FQ35667283-D18BBEFE-BAE5-4C79-855E-AE386EE9F4FBQ36308489-D4062872-8840-4947-8341-2EDA2F870C15Q36386588-E8DA3CFC-9606-421F-9A53-37781ABDF19FQ36540807-903537BC-DED7-4876-9D73-7050CE8E8F7FQ36604516-2013624B-414F-4697-9B7F-D52B586F6307Q36647328-CE7F0A06-CDC0-4681-A992-F3A6352044D3Q36924916-AF599349-21B3-4E1A-9228-67890EA2FD51Q37991200-2D419263-7768-401C-8198-5360D6A45D8BQ38235996-FC24C3A6-F54E-4747-A3EE-3CE7987C36FDQ38436237-8F6AE35A-CBED-451D-9162-53E8506D6092Q38792099-F6E902B0-9C52-465C-B263-0A68F23573F3Q38973930-3B442925-1F09-4820-AC01-CA89E1745751Q39431976-ADE830A1-7217-485B-8C61-81C23D5A62B5Q39735567-19B37256-DEAB-4023-ACDD-E9686F8C5385Q40388355-CE90D607-41F0-48DB-B186-C3B572ECC5D5Q40413919-E2903C6A-CA23-427B-B54D-484D917C7CA1Q43418239-79B338F4-B818-4934-B943-A01A1784597CQ43823700-BCED4751-8D84-4B8B-86B7-F8E245E1FE40Q43905798-95225934-9CA1-4E5F-A65D-9C0B69CE1C6DQ44256403-2BB85672-7DFA-4278-BB88-14D0B444D554Q44601898-503E6A21-C6B6-4E81-869A-A51F96D97E11Q44968322-8D191A63-2119-4F51-B113-CB822A3371E1Q46277645-880160E2-1F80-4352-9C21-9BD09A45A9C3Q46505328-7548E24E-73BF-46FC-BDDF-4F9E41EB5245Q47806926-65ED66F9-ED44-4C9B-947E-3FE21CA8E5C1Q47826246-C6CBFBEB-8AC2-439A-A948-1AD749F28693Q50531693-3B2796F3-64CF-4850-816B-EA915E4B5A8DQ50552934-8C5880B4-07CC-464E-97FD-500D55CD4736Q50586946-A5B67825-F59E-4454-AF70-83CA2E3075E6Q50744266-2DE06A3C-99B2-4552-8AA1-52D4FDD5D472Q50893685-F8FD2952-754D-4B2A-A3E4-68C3CFF93ABBQ50912958-CC91E3C4-9ED4-424E-8487-651B8A8DDF1DQ51010266-BDE14587-EF9F-4BAF-81A3-38653305CF20Q51035991-EF6B3515-D7EB-4DA3-826E-620F93C79A05
P2860
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@en
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@nl
type
label
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@en
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@nl
prefLabel
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@en
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@nl
P2093
P2860
P356
P1433
P1476
Screening for trisomies 21, 18 ...... y-associated plasma protein-A.
@en
P2093
Catalina Valencia
Dave Wright
Karl O Kagan
Kypros H Nicolaides
P2860
P304
P356
10.1093/HUMREP/DEN224
P407
P50
P577
2008-06-10T00:00:00Z